 Lans left CMU to found Cellomics and created High Content Screening (HCS) for large-scale phenotypic screening for drug discovery and development which later became part of ThermoFisher.Cellumen was the next company founded by Lans to apply systems cell biology to both drug safety testing (now part of Cyprotex) and cancer diagnostics.The cancer diagnostics unit was spun off as Cernostics and they created a test for Barrett’s Esophagus.